FrederickLundryLockeMD

Hematologic Oncology

Senior Member and Chair Department of Blood and Marrow Transplant and Cellular Immunotherapy and Co-Leader, Immunology Program Moffitt Cancer Center

Request Appointment

Overview of Dr. Locke

Dr. Frederick Locke is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Wayne State University School of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, non-hodgkin's lymphoma, immunology, and chimeric antigen receptor (CAR) t-cell therapy.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(229) 466-4565

Fax+1 813-745-8468

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
Wayne State University School of MedicineResidency, Internal Medicine, 2002 - 2006
Wayne State University School of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2010 - 2025
IL State Medical License 2006 - 2011
MI State Medical License 2002 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Miles for Moffitt Scientist Award Moffitt Foundation, 2015
Internal Research Grant Award Recipient American Cancer Society, 2012
Clinical Research Training Institute Participant American Society of Hematology, 2011
Young Investigator Award American Society of Clinical Oncology, 2010
Award for Molecular and Translational Research Cancer Education Consortium, 2009
Join now to see all

Clinical Trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) Start of enrollment: 2016 Sep 27
Completed
Early Phase 1
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

49 citations
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch
Blood Advances. 2020-04-14
19 citations
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Kai Rejeski, Ariel Perez, Gloria Iacoboni, Viktoria Blumenberg, Veit L Bücklein
Science Advances. 2023-09-22
9 citations
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Kai Rejeski, Yucai Wang, Doris K Hansen, Gloria Iacoboni, Emmanuel Bachy
Blood Advances. 2024-04-23

Abstracts/Posters

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymph...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Phase 3 Study Results Show Metabolic Tumor Volume Improves Prognosis Compared to SPD in Second-Line R/R LBCLDecember 11th, 2022
$Time to CAR T-cell Therapy May Impact Outcomes for Patients with Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis$
Time to CAR T-cell Therapy May Impact Outcomes for Patients with Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR AnalysisDecember 11th, 2022
$Body of Evidence Grows from ZUMA-7 Study Supporting Initial Treatment with Kite’s Yescarta® CAR T-cell Therapy for Patients with Relapsed or Refractory Large B-cell Lymphoma$
Body of Evidence Grows from ZUMA-7 Study Supporting Initial Treatment with Kite’s Yescarta® CAR T-cell Therapy for Patients with Relapsed or Refractory Large B-cell LymphomaDecember 11th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
Society for Immunotherapy of Cancer
Member
American Society of Blood and Marrow Transplantation - ASBMT
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PPO
Network Health Plan HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment